Mostrar el registro sencillo del ítem

Artículo

dc.creatorZhang, Qianges
dc.creatorPizzorno, Andréses
dc.creatorMiorin, Lisaes
dc.creatorBastard, Paules
dc.creatorGervais, Adriánes
dc.creatorLe Voyer, Tomes
dc.creatorRetamar Gentil, Pilares
dc.creatorSánchez Céspedes, Javieres
dc.creatorCordero Matia, María Elisaes
dc.creatorCasanova, Jean-Laurentes
dc.date.accessioned2023-10-06T13:34:20Z
dc.date.available2023-10-06T13:34:20Z
dc.date.issued2022
dc.identifier.citationZhang, Q., Pizzorno, A., Miorin, L., Bastard, P., Gervais, A., Le Voyer, T.,...,Casanova, J. (2022). Autoantibodies against type I IFNs in patients with critical influenza pneumonia. JOURNAL OF EXPERIMENTAL MEDICINE, 219 (11), e20220514. https://doi.org/10.1084/jem.20220514.
dc.identifier.issn0022-1007es
dc.identifier.issn1540-9538es
dc.identifier.urihttps://hdl.handle.net/11441/149540
dc.description.abstractAutoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6–73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients’ autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 × 10−5 ), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10−5 ), especially those <70 yr old (OR = 139.9, P = 3.1 × 10−10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life threatening influenza pneumonia in patients <70 yr old.es
dc.formatapplication/pdfes
dc.format.extent29 p.es
dc.language.isoenges
dc.publisherROCKEFELLER UNIV PRESSes
dc.relation.ispartofJOURNAL OF EXPERIMENTAL MEDICINE, 219 (11), e20220514.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAutoantibodieses
dc.subjectType I IFNses
dc.subjectPneumoniaes
dc.subjectCritical influenza pneumoniaes
dc.titleAutoantibodies against type I IFNs in patients with critical influenza pneumoniaes
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.publisherversionhttps://rupress.org/jem/article/219/11/e20220514/213469/Autoantibodies-against-type-I-IFNs-in-patientses
dc.identifier.doi10.1084/jem.20220514es
dc.journaltitleJOURNAL OF EXPERIMENTAL MEDICINEes
dc.publication.volumen219es
dc.publication.issue11es
dc.publication.initialPagee20220514es

FicherosTamañoFormatoVerDescripción
Autoantibodies against.pdf3.208MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional